Overview

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)
Phase:
Phase 3
Details
Lead Sponsor:
CymaBay Therapeutics, Inc.
Treatments:
Seladelpar